{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:22:47Z","timestamp":1794651767377,"version":"4.9.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41585-023-00847-7","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:02:33Z","timestamp":1707210153000},"page":"391-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Molecular profile of bladder cancer progression to clinically aggressive subtypes"],"prefix":"10.1038","volume":"21","author":[{"given":"Charles C.","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangkyou","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-9173","authenticated-orcid":false,"given":"Bogdan","family":"Czerniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"847_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"847_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"847_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"847_CR4","unstructured":"Board, W. C. O. T. E. Urinary and Male Genital Tumours. 5th edn, (International Agency for Research on Cancer, 2022)."},{"key":"847_CR5","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"847_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"847_CR7","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","volume":"70","author":"D Lindgren","year":"2010","unstructured":"Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463\u20133472 (2010).","journal-title":"Cancer Res."},{"key":"847_CR8","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sjodahl","year":"2012","unstructured":"Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"847_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","volume":"183","author":"G Sjodahl","year":"2013","unstructured":"Sjodahl, G. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol. 183, 681\u2013691 (2013).","journal-title":"Am. J. Pathol."},{"key":"847_CR10","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat, E. et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 400, 1712\u20131721 (2022).","journal-title":"Lancet"},{"key":"847_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"847_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo, C. C. et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci. Rep. 10, 9743 (2020).","journal-title":"Sci. Rep."},{"key":"847_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 e525 (2017).","journal-title":"Cell"},{"key":"847_CR14","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110\u20133115 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"847_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"847_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Research Network.","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"847_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","volume":"143","author":"CC Guo","year":"2019","unstructured":"Guo, C. C. & Czerniak, B. Bladder cancer in the genomic era. Arch. Pathol. Lab. Med. 143, 695\u2013704 (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"847_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","volume":"11","author":"B Czerniak","year":"2016","unstructured":"Czerniak, B., Dinney, C. & McConkey, D. Origins of bladder cancer. Annu. Rev. Pathol. 11, 149\u2013174 (2016).","journal-title":"Annu. Rev. Pathol."},{"key":"847_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.5858\/2006-130-844-DPOBCP","volume":"130","author":"PE Spiess","year":"2006","unstructured":"Spiess, P. E. & Czerniak, B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch. Pathol. Lab. Med. 130, 844\u2013852 (2006).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"847_CR20","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","volume":"22","author":"MB Amin","year":"2009","unstructured":"Amin, M. B. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol. 22, S96\u2013S118 (2009).","journal-title":"Mod. Pathol."},{"key":"847_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng.3503","volume":"48","author":"HA Al-Ahmadie","year":"2016","unstructured":"Al-Ahmadie, H. A. et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat. Genet. 48, 356\u2013358 (2016).","journal-title":"Nat. Genet."},{"key":"847_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","volume":"4","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits, J. et al. Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile. Eur. Urol. Oncol. 4, 297\u2013300 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"847_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0772-8","volume":"21","author":"JT Matulay","year":"2019","unstructured":"Matulay, J. T., Narayan, V. M. & Kamat, A. M. Clinical and genomic considerations for variant histology in bladder cancer. Curr. Oncol. Rep. 21, 23 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"847_CR24","doi-asserted-by":"publisher","first-page":"18.e15","DOI":"10.1016\/j.urolonc.2014.10.001","volume":"33","author":"MF Monn","year":"2015","unstructured":"Monn, M. F. et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol. Oncol. 33, 18.e15\u201318.e20 (2015).","journal-title":"Urol. Oncol."},{"key":"847_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","volume":"53","author":"T Takahara","year":"2021","unstructured":"Takahara, T., Murase, Y. & Tsuzuki, T. Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology 53, 56\u201366 (2021).","journal-title":"Pathology"},{"key":"847_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MOU.0b013e328363e415","volume":"23","author":"DL Willis","year":"2013","unstructured":"Willis, D. L., Porten, S. P. & Kamat, A. M. Should histologic variants alter definitive treatment of bladder cancer? Curr. Opin. Urol. 23, 435\u2013443 (2013).","journal-title":"Curr. Opin. Urol."},{"key":"847_CR27","unstructured":"Grignon DJ, A.-A. H. et al. Tumors of the Urinary Tract. 4th edn, 77\u2013133 (IARC Press, 2016)."},{"key":"847_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.path.2022.07.004","volume":"15","author":"CC Guo","year":"2022","unstructured":"Guo, C. C. & Czerniak, B. Molecular taxonomy and immune checkpoint therapy in bladder cancer. Surg. Pathol. Clin. 15, 681\u2013694 (2022).","journal-title":"Surg. Pathol. Clin."},{"key":"847_CR29","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","volume":"27","author":"CC Guo","year":"2019","unstructured":"Guo, C. C. et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer. Cell Rep. 27, 1781\u20131793.e1784 (2019).","journal-title":"Cell Rep."},{"key":"847_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.humpath.2018.05.005","volume":"79","author":"G Wang","year":"2018","unstructured":"Wang, G. et al. Small cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 81 cases. Hum. Pathol. 79, 57\u201365 (2018).","journal-title":"Hum. Pathol."},{"key":"847_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","volume":"72","author":"TJ Moss","year":"2017","unstructured":"Moss, T. J. et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur. Urol. 72, 641\u2013649 (2017).","journal-title":"Eur. Urol."},{"key":"847_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","volume":"70","author":"CC Guo","year":"2016","unstructured":"Guo, C. C. et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol. 70, 611\u2013620 (2016).","journal-title":"Eur. Urol."},{"key":"847_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"DJ McConkey","year":"2016","unstructured":"McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855\u2013862 (2016).","journal-title":"Eur. Urol."},{"key":"847_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania, V. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12, 105\u2013117 (2016).","journal-title":"EBioMedicine"},{"key":"847_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The Cancer Genome Atlas pan-cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"847_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"TJ Hudson","year":"2010","unstructured":"Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993\u2013998 (2010).","journal-title":"Nature"},{"key":"847_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90\u201394 (2011).","journal-title":"Nature"},{"key":"847_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature13600","volume":"512","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155\u2013160 (2014).","journal-title":"Nature"},{"key":"847_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nmeth.1315","volume":"6","author":"F Tang","year":"2009","unstructured":"Tang, F. et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat. Methods 6, 377\u2013382 (2009).","journal-title":"Nat. Methods"},{"key":"847_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01075-1","volume":"14","author":"CG Williams","year":"2022","unstructured":"Williams, C. G., Lee, H. J., Asatsuma, T., Vento-Tormo, R. & Haque, A. An introduction to spatial transcriptomics for biomedical research. Genome Med. 14, 68 (2022).","journal-title":"Genome Med."},{"key":"847_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"847_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"847_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3322\/caac.20029","volume":"59","author":"M Cianfrocca","year":"2009","unstructured":"Cianfrocca, M. & Gradishar, W. New molecular classifications of breast cancer. CA Cancer J. Clin. 59, 303\u2013313 (2009).","journal-title":"CA Cancer J. Clin."},{"key":"847_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskj\u00f8t","year":"2003","unstructured":"Dyrskj\u00f8t, L. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33, 90\u201396 (2003).","journal-title":"Nat. Genet."},{"key":"847_CR45","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","volume":"11","author":"E Blaveri","year":"2005","unstructured":"Blaveri, E. et al. Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11, 4044\u20134055 (2005).","journal-title":"Clin. Cancer Res."},{"key":"847_CR46","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.celrep.2019.01.095","volume":"26","author":"T Majewski","year":"2019","unstructured":"Majewski, T. et al. Whole-organ genomic characterization of mucosal field effects initiating bladder carcinogenesis. Cell Rep. 26, 2241\u20132256.e2244 (2019).","journal-title":"Cell Rep."},{"key":"847_CR47","doi-asserted-by":"publisher","first-page":"101201","DOI":"10.1016\/j.isci.2020.101201","volume":"23","author":"G Yang","year":"2020","unstructured":"Yang, G. et al. Urothelial-to-neural plasticity drives progression to small cell bladder cancer. iScience 23, 101201 (2020).","journal-title":"iScience"},{"key":"847_CR48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5858\/arpa.2015-0085-OA","volume":"140","author":"J Sanfrancesco","year":"2016","unstructured":"Sanfrancesco, J. et al. Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch. Pathol. Lab. Med. 140, 543\u2013551 (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"847_CR49","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.juro.2007.08.038","volume":"178","author":"JL Wright","year":"2007","unstructured":"Wright, J. L. et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J. Urol. 178, 2302\u20132306 (2007). discussion 2307.","journal-title":"J. Urol."},{"key":"847_CR50","doi-asserted-by":"publisher","first-page":"454792","DOI":"10.1155\/2010\/454792","volume":"2010","author":"J Wang","year":"2010","unstructured":"Wang, J., Wang, F. W., Lagrange, C. A., Hemstreet Iii, G. P. & Kessinger, A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010, 454792 (2010).","journal-title":"Sarcoma"},{"key":"847_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/path.6060","volume":"259","author":"J Fontugne","year":"2023","unstructured":"Fontugne, J. et al. Progression-associated molecular changes in basal\/squamous and sarcomatoid bladder carcinogenesis. J. Pathol. 259, 455\u2013467 (2023).","journal-title":"J. Pathol."},{"key":"847_CR52","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","DOI":"10.1038\/nature13480"},{"key":"847_CR53","doi-asserted-by":"publisher","first-page":"80164","DOI":"10.18632\/oncotarget.13284","volume":"7","author":"AE Ochoa","year":"2016","unstructured":"Ochoa, A. E. et al. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget 7, 80164\u201380174 (2016).","journal-title":"Oncotarget"},{"key":"847_CR54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128\u2013134 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"847_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871\u2013890 (2009).","journal-title":"Cell"},{"key":"847_CR56","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1074\/jbc.M112.408104","volume":"288","author":"MN Tran","year":"2013","unstructured":"Tran, M. N. et al. The p63 protein isoform \u0394Np63\u03b1 inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J. Biol. Chem. 288, 3275\u20133288 (2013).","journal-title":"J. Biol. Chem."},{"key":"847_CR57","doi-asserted-by":"publisher","first-page":"14910","DOI":"10.1074\/jbc.C800074200","volume":"283","author":"M Korpal","year":"2008","unstructured":"Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910\u201314914 (2008).","journal-title":"J. Biol. Chem."},{"key":"847_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304.e296 (2018).","journal-title":"Cell"},{"key":"847_CR59","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1073\/pnas.1525735113","volume":"113","author":"M Bi","year":"2016","unstructured":"Bi, M. et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc. Natl Acad. Sci. USA 113, 2170\u20132175 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"847_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6006","volume":"5","author":"S Jones","year":"2014","unstructured":"Jones, S. et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Commun. 5, 5006 (2014).","journal-title":"Nat. Commun."},{"key":"847_CR61","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","volume":"22","author":"MP Mak","year":"2016","unstructured":"Mak, M. P. et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res. 22, 609\u2013620 (2016).","journal-title":"Clin. Cancer Res."},{"key":"847_CR62","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.urolonc.2019.09.025","volume":"37","author":"V Genitsch","year":"2019","unstructured":"Genitsch, V. et al. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urol. Oncol. 37, 826\u2013836 (2019).","journal-title":"Urol. Oncol."},{"key":"847_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.humpath.2018.05.005","volume":"79","author":"G Wang","year":"2018","unstructured":"Wang, G. et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum. Pathol. 79, 57\u201365 (2018).","journal-title":"Hum. Pathol."},{"key":"847_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sjodahl","year":"2017","unstructured":"Sjodahl, G., Eriksson, P., Liedberg, F. & Hoglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"847_CR65","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","volume":"25","author":"J Batista da Costa","year":"2019","unstructured":"Batista da Costa, J. et al. Molecular characterization of neuroendocrine-like bladder cancer. Clin. Cancer Res. 25, 3908\u20133920 (2019).","journal-title":"Clin. Cancer Res."},{"key":"847_CR66","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","volume":"24","author":"MT Chang","year":"2018","unstructured":"Chang, M. T. et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin. Cancer Res. 24, 1965\u20131973 (2018).","journal-title":"Clin. Cancer Res."},{"key":"847_CR67","doi-asserted-by":"publisher","first-page":"8402","DOI":"10.1073\/pnas.0600906103","volume":"103","author":"NA Siddall","year":"2006","unstructured":"Siddall, N. A., McLaughlin, E. A., Marriner, N. L. & Hime, G. R. The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. Proc. Natl Acad. Sci. USA 103, 8402\u20138407 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"847_CR68","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ncb3533","volume":"19","author":"T Celi\u00e0-Terrassa","year":"2017","unstructured":"Celi\u00e0-Terrassa, T. et al. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis. Nat. Cell Biol. 19, 711\u2013723 (2017).","journal-title":"Nat. Cell Biol."},{"key":"847_CR69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nature08195","volume":"460","author":"KR Cordes","year":"2009","unstructured":"Cordes, K. R. et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460, 705\u2013710 (2009).","journal-title":"Nature"},{"key":"847_CR70","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1242\/dev.144337","volume":"144","author":"M Rajman","year":"2017","unstructured":"Rajman, M. & Schratt, G. MicroRNAs in neural development: from master regulators to fine-tuners. Development 144, 2310\u20132322 (2017).","journal-title":"Development"},{"key":"847_CR71","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","volume":"16","author":"MD Borromeo","year":"2016","unstructured":"Borromeo, M. D. et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 16, 1259\u20131272 (2016).","journal-title":"Cell Rep."},{"key":"847_CR72","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289\u2013297 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"847_CR73","first-page":"02830","volume":"S0302-2838","author":"M Feng","year":"2023","unstructured":"Feng, M. et al. Identification of lineage specific transcriptional factor defined molecular subtypes in small cell bladder cancer. Eur. Urol. S0302-2838, 02830 (2023).","journal-title":"Eur. Urol."},{"key":"847_CR74","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.euf.2017.03.007","volume":"4","author":"DS Priemer","year":"2018","unstructured":"Priemer, D. S. et al. Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small-cell carcinoma of the urinary bladder and urothelial carcinoma. Eur. Urol. Focus. 4, 880\u2013888 (2018).","journal-title":"Eur. Urol. Focus."},{"key":"847_CR75","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0002-9440(10)62369-3","volume":"166","author":"L Cheng","year":"2005","unstructured":"Cheng, L. et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am. J. Pathol. 166, 1533\u20131539 (2005).","journal-title":"Am. J. Pathol."},{"key":"847_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0665-0","volume":"16","author":"SR Ma","year":"2017","unstructured":"Ma, S. R. et al. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol. Cancer 16, 99 (2017).","journal-title":"Mol. Cancer"},{"key":"847_CR77","unstructured":"ClinicalTrials.gov. Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer clinical trials.gov NCT05312671. https:\/\/clinicaltrials.gov\/study\/NCT05312671 (2023)."},{"key":"847_CR78","first-page":"201915770","volume":"117","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. Proc. Natl Acad. Sci. USA 117, 201915770 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"847_CR79","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/CU9.0000000000000125","volume":"16","author":"T Muranaka","year":"2022","unstructured":"Muranaka, T. et al. Clinical characteristics and treatment outcomes of patients with small cell carcinoma of the urinary bladder. Curr. Urol. 16, 136\u2013141 (2022).","journal-title":"Curr. Urol."},{"key":"847_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman, D. S., Beltran, H., Demichelis, F. & Rubin, M. A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 23, 1\u201310 (2017).","journal-title":"Nat. Med."},{"key":"847_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland, A. S. et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38, 60\u201378.e12 (2020).","journal-title":"Cancer Cell"},{"key":"847_CR82","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clgc.2020.10.009","volume":"19","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits, J. et al. Small cell bladder cancer response to second-line and beyond checkpoint inhibitor therapy: retrospective experience. Clin. Genitourin. Cancer 19, 176\u2013181 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"847_CR83","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75, 961\u2013964 (2019).","journal-title":"Eur. Urol."},{"key":"847_CR84","unstructured":"clinicaltrials.gov. National Cancer Institute. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (NCT05058651). https:\/\/clinicaltrials.gov\/study\/NCT05058651 (2024)."},{"key":"847_CR85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits, J. H. et al. Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl. Immunohistochem. Mol. Morphol. 29, 619\u2013625 (2021).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"847_CR86","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu, G. et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell 31, 270\u2013285 (2017).","journal-title":"Cancer Cell"},{"key":"847_CR87","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-18-4140","volume":"25","author":"MD Chalishazar","year":"2019","unstructured":"Chalishazar, M. D. et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin. Cancer Res. 25, 5107\u20135121 (2019).","journal-title":"Clin. Cancer Res."},{"key":"847_CR88","unstructured":"Moch H, H. P., Ulbright TM, Retuer VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th edn, 77\u2013133 (IARC Press, 2016)."},{"key":"847_CR89","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.bbamcr.2014.06.001","volume":"1843","author":"KH Lee","year":"2014","unstructured":"Lee, K. H. et al. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim. Biophys. Acta Mol. Cell Res. 1843, 2055\u20132066 (2014).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"847_CR90","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/CS20130580","volume":"127","author":"F Savi","year":"2014","unstructured":"Savi, F. et al. miR-296\/scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. Clin. Sci. 127, 233\u2013242 (2014).","journal-title":"Clin. Sci."},{"key":"847_CR91","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1158\/1078-0432.CCR-10-0993","volume":"17","author":"JJ Wei","year":"2011","unstructured":"Wei, J. J. et al. Regulation of HMGA1 expression by MicroRNA-296 affects prostate cancer growth and invasion. Clin. Cancer Res. 17, 1297\u20131305 (2011).","journal-title":"Clin. Cancer Res."},{"key":"847_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/onc.2011.209","volume":"31","author":"V Vaira","year":"2012","unstructured":"Vaira, V. et al. MiR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 31, 27\u201338 (2012).","journal-title":"Oncogene"},{"key":"847_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133576","volume":"10","author":"C Gentili","year":"2015","unstructured":"Gentili, C. et al. Chromosome missegregation associated with RUVBL1 deficiency. PLoS ONE\u00a010, e0133576 (2015).","journal-title":"PLoS ONE"},{"key":"847_CR94","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3892\/ijo.2014.2380","volume":"45","author":"K Taniuchi","year":"2014","unstructured":"Taniuchi, K. et al. RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell invasion. Int. J. Oncol. 45, 1945\u20131954 (2014).","journal-title":"Int. J. Oncol."},{"key":"847_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","volume":"20","author":"JS Ross","year":"2014","unstructured":"Ross, J. S. et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res. 20, 68\u201375 (2014).","journal-title":"Clin. Cancer Res."},{"key":"847_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","volume":"77","author":"S Isharwal","year":"2018","unstructured":"Isharwal, S. et al. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum. Pathol. 77, 63\u201369 (2018).","journal-title":"Hum. Pathol."},{"key":"847_CR97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","volume":"80","author":"U Zinnall","year":"2018","unstructured":"Zinnall, U. et al. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum. Pathol. 80, 55\u201364 (2018).","journal-title":"Hum. Pathol."},{"key":"847_CR98","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/modpathol.2013.201","volume":"27","author":"SA Schneider","year":"2014","unstructured":"Schneider, S. A. et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod. Pathol. 27, 758\u2013764 (2014).","journal-title":"Mod. Pathol."},{"key":"847_CR99","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4161\/cbt.29687","volume":"15","author":"M de Martino","year":"2014","unstructured":"de Martino, M. et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol. Ther. 15, 1239\u20131247 (2014).","journal-title":"Cancer Biol. Ther."},{"key":"847_CR100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","volume":"51","author":"S Oudard","year":"2015","unstructured":"Oudard, S. et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur. J. Cancer 51, 45\u201354 (2015).","journal-title":"Eur. J. Cancer"},{"key":"847_CR101","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","volume":"73","author":"I Kinde","year":"2013","unstructured":"Kinde, I. et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 73, 7162\u20137167 (2013).","journal-title":"Cancer Res."},{"key":"847_CR102","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","volume":"65","author":"Y Allory","year":"2014","unstructured":"Allory, Y. et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 65, 360\u2013366 (2014).","journal-title":"Eur. Urol."},{"key":"847_CR103","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00428-016-2001-2","volume":"469","author":"D Nguyen","year":"2016","unstructured":"Nguyen, D. et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 469, 427\u2013434 (2016).","journal-title":"Virchows Arch."},{"key":"847_CR104","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/biomedicines10040910","volume":"10","author":"JH Chung","year":"2022","unstructured":"Chung, J. H., Lee, C. U., Lee, D. H. & Song, W. Expression and prognostic implication of PD-L1 in patients with urothelial carcinoma with variant histology (squamous differentiation or micropapillary) undergoing radical cystectomy. Biomedicines 10, 910 (2022).","journal-title":"Biomedicines"},{"key":"847_CR105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2022.05.022","volume":"171","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. Eur. J. Cancer 171, 133\u2013142 (2022).","journal-title":"Eur. J. Cancer"},{"key":"847_CR106","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/ajcp\/aqx029","volume":"147","author":"MD Fox","year":"2017","unstructured":"Fox, M. D. et al. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases. Am. J. Clin. Pathol. 147, 500\u2013506 (2017).","journal-title":"Am. J. Clin. Pathol."},{"key":"847_CR107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/BLC-190258","volume":"6","author":"LN Diamantopoulos","year":"2020","unstructured":"Diamantopoulos, L. N. et al. Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bladder Cancer 6, 71\u201381 (2020).","journal-title":"Bladder Cancer"},{"key":"847_CR108","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00428-017-2190-3","volume":"471","author":"JI Warrick","year":"2017","unstructured":"Warrick, J. I. et al. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. Virchows Arch. 471, 337\u2013345 (2017).","journal-title":"Virchows Arch."},{"key":"847_CR109","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","volume":"124","author":"MY Teo","year":"2021","unstructured":"Teo, M. Y. et al. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br. J. Cancer 124, 1214\u20131221 (2021).","journal-title":"Br. J. Cancer"},{"key":"847_CR110","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/bjc.2015.436","volume":"114","author":"F Trillsch","year":"2016","unstructured":"Trillsch, F. et al. E-cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. Br. J. Cancer 114, 213\u2013220 (2016).","journal-title":"Br. J. Cancer"},{"key":"847_CR111","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"847_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","volume":"85","author":"DN Palsgrove","year":"2019","unstructured":"Palsgrove, D. N. et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum. Pathol. 85, 1\u20139 (2019).","journal-title":"Hum. Pathol."},{"key":"847_CR113","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41379-022-01038-2","volume":"35","author":"USCAP 2022 Abstracts.","year":"2022","unstructured":"USCAP 2022 Abstracts. Genitourinary pathology (including renal tumors) (522-659). Mod. Pathol. 35, 657\u2013806 (2022).","journal-title":"Mod. Pathol."},{"key":"847_CR114","doi-asserted-by":"publisher","first-page":"496.e491","DOI":"10.1016\/j.urolonc.2015.05.026","volume":"33","author":"M Taga","year":"2015","unstructured":"Taga, M. et al. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Urol. Oncol. 33, 496.e491\u2013499 (2015).","journal-title":"Urol. Oncol."},{"key":"847_CR115","doi-asserted-by":"publisher","first-page":"15176","DOI":"10.1016\/S0021-9258(18)42162-X","volume":"267","author":"A Weller","year":"1992","unstructured":"Weller, A., Isenmann, S. & Vestweber, D. Cloning of the mouse endothelial selectins. Expression of both E- and P-selectin is inducible by tumor necrosis factor alpha. J. Biol. Chem. 267, 15176\u201315183 (1992).","journal-title":"J. Biol. Chem."},{"key":"847_CR116","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/labinvest.2008.27","volume":"88","author":"Majewski","year":"2008","unstructured":"Majewski et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab. Invest 88, 694\u2013721 (2008).","journal-title":"Lab. Invest"},{"key":"847_CR117","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","volume":"174","author":"Robertson","year":"2018","unstructured":"Robertson et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174, 1033 (2018).","journal-title":"Cell"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00847-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00847-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00847-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:03:19Z","timestamp":1720083799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00847-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":117,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1038\/s41585-023-00847-7","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"15 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}